Syndax pharmaceuticals inc (SNDX)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15
ASSETS
Current assets:
Cash and cash equivalents

44,629

24,609

30,581

26,666

58,116

33,769

26,705

32,204

27,981

35,168

20,732

22,988

22,356

23,844

12,753

14,441

23,187

23,179

Restricted cash

115

-

101

101

101

101

101

101

100

106

100

101

102

151

154

54

52

54

Short-term investments

54,376

35,166

41,657

53,854

34,626

47,142

62,894

66,181

85,242

94,806

99,862

106,967

70,429

81,486

102,814

111,016

110,483

63,310

Prepaid expenses and other current assets

5,086

2,556

2,511

5,154

4,790

2,334

6,146

6,210

5,983

3,362

3,277

4,111

4,170

3,029

1,546

1,868

2,045

1,464

Total current assets

104,206

62,331

74,850

85,775

97,633

83,346

95,846

104,696

119,306

133,442

123,971

134,167

97,057

108,510

117,267

127,379

135,767

88,007

Long-term investments

-

-

-

-

-

-

-

-

-

3,246

-

-

-

-

-

-

-

-

Property and equipment, net

259

281

304

327

350

373

396

415

422

267

286

260

234

260

283

304

275

88

Right-of-use asset, net

608

716

826

1,087

1,208

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

82

197

401

201

201

219

225

259

229

231

236

239

376

243

179

173

217

1,808

Total assets

105,155

63,525

76,381

87,390

99,392

83,938

96,467

105,370

119,957

137,186

124,493

134,666

97,667

109,013

117,729

127,856

136,259

89,903

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable

8,998

6,178

6,757

2,276

4,350

1,439

3,180

5,297

2,590

2,232

2,246

3,362

2,741

2,375

2,010

1,588

2,225

1,452

Accrued expenses and other current liabilities

7,795

10,195

9,542

13,168

9,266

13,149

12,319

12,484

12,800

11,993

10,741

6,923

7,028

6,771

5,917

3,745

3,590

2,175

Current portion of deferred revenue

1,517

1,517

1,517

1,517

1,517

1,517

1,517

1,517

-

1,573

-

-

-

-

-

-

-

-

Current portion of right-of-use liability

480

478

478

530

525

-

-

-

-

-

-

-

-

-

-

-

-

-

Current portion of deferred revenue

-

-

-

-

-

-

-

-

1,517

-

1,220

1,220

1,220

1,220

1,220

1,220

1,220

1,220

Total current liabilities

18,790

18,368

18,294

17,491

15,658

16,105

17,016

19,298

16,907

15,798

14,207

11,505

10,989

10,366

9,147

6,553

7,035

4,847

Long-term liabilities:
Deferred revenue, less current portion

12,754

13,133

13,513

13,892

14,271

14,650

15,029

15,409

-

16,759

-

-

-

-

-

-

-

-

Right-of-use liability, less current portion

306

419

525

725

830

-

-

-

-

-

-

-

-

-

-

-

-

-

Loan payable

19,792

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,848

Deferred revenue, less current portion

-

-

-

-

-

-

-

-

15,788

-

13,305

13,610

13,915

14,220

14,525

14,830

15,135

15,440

Other long-term liabilities

4

5

6

7

7

136

148

311

312

310

267

214

148

288

223

232

243

70

Total long-term liabilities

32,856

13,557

14,044

14,624

15,108

14,786

15,177

15,720

16,100

17,069

13,572

13,824

14,063

14,508

14,748

15,062

15,378

18,358

Total liabilities

51,646

31,925

32,338

32,115

30,766

30,891

32,193

35,018

33,007

32,867

27,779

25,329

25,052

24,874

23,895

21,615

22,413

23,205

Commitments

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

Convertible preferred stock (Note 12)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

319,113

Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

Common stock, $0.0001 par value, 100,000,000 shares authorized; 30,240,838 and 27,140,484 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

3

3

3

3

3

2

2

2

2

2

2

2

2

2

2

2

2

1

Additional paid-in capital

-

-

-

-

-

-

484,893

-

-

-

-

-

-

-

-

-

-

-

Additional paid-in capital

564,164

527,067

525,485

523,855

522,340

492,493

-

473,686

472,026

470,571

443,692

441,218

390,894

389,374

388,210

385,556

384,767

-

Accumulated other comprehensive income

48

-

25

58

8

-25

-35

-89

-218

-143

28

36

-2

56

100

192

228

28

Accumulated deficit

-510,706

-495,470

-481,470

-468,641

-453,725

-439,423

-420,586

-403,247

-384,860

-366,111

-347,008

-331,919

-318,279

-305,293

-294,478

-279,509

-271,151

-259,675

Total stockholders’ equity

53,509

31,600

44,043

55,275

68,626

53,047

64,274

70,352

86,950

104,319

96,714

109,337

72,615

84,139

93,834

106,241

113,846

-252,415

Total liabilities and stockholders’ equity

105,155

63,525

76,381

87,390

99,392

83,938

96,467

105,370

119,957

137,186

124,493

134,666

97,667

109,013

117,729

127,856

136,259

89,903